SCHEMBL521781

SCHEMBL521781

CC(C)(C)OC(=O)N1C2CC[C@@H]1C(=O)C2

nearest known ligand 0.54

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.54
CHRM1 P11229 1/20 0.54
CHRM3 P20309 1/20 0.54
PREP P48147 4/20 0.44
HSD11B1 P28845 1/20 0.42
KDM4E B2RXH2 1/20 0.37
MAPT P10636 1/20 0.37
THRB P10828 1/20 0.37
HPGD P15428 1/20 0.36
GPR119 Q8TDV5 1/20 0.35
ELANE P08246 1/20 0.35
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1445058 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL521276 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30000644 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL24616534 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL521435 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL24616413 1.00 CHRM2 (0.54) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL30278375 0.87 CHRM2 (0.51) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL21588272 0.87 CHRM2 (0.51) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL31045746 0.86 CHRM2 (0.55) CHRM2CHRM1CHRM3PREPHSD11B1
SCHEMBL21308104 0.86 CHRM2 (0.50) CHRM2CHRM1CHRM3PREPHSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104744480-B 7-azoniabicyclo [2.2.1] heptane derivatives, process for their preparation, and their pharmaceutical use 西伦制药公司 2021-02-12 CN disclosed
EP-2528921-B1 7-AZONIABICYCLO [2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS INC (US) 2017-10-18 EP disclosed
US-20160296497-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS, INC. 2016-10-13 US disclosed
US-9320731-B2 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof THERON PHARMACEUTICALS, INC. (US) 2016-04-26 US disclosed
US-20140249195-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS, INC (US) 2014-09-04 US disclosed
US-8742134-B2 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof THERON PHARMACEUTICALS, INC. (US) 2014-06-03 US disclosed
US-8742131-B2 7-azoniabicyclo [2.2.1] heptane derivatives, methods of production, and pharmaceutical uses thereof THERON PHARMACEUTICALS, INC. (US) 2014-06-03 US disclosed
US-20130157989-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS, INC. (US) 2013-06-20 US disclosed
US-8426611-B2 7-azoniabicyclo[2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof THERON PHARMACEUTICALS INC. (US) 2013-04-23 US disclosed
US-20130059898-A1 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-20120029044-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF THERON PHARMACEUTICALS INC. 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249195-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20130059898-A1 7-AZONIABICYCLO [2.2.1] HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20160296497-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20130157989-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885
US-20120029044-A1 7-AZONIABICYCLO[2.2.1]HEPTANE DERIVATIVES, METHODS OF PRODUCTION, AND PHARMACEUTICAL USES THEREOF CHRM3, CHRM2, CHRM1 CHRM2 2/4885CHRM1 3/4885CHRM3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.